Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE To compare the efficacy and safety of glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS In this prospective randomized controlled study, we randomly assigned patients with GDM at 13–33 weeks gestation and whose blood glucose was poorly controlled by diet to receive either glyburide or metformin. If optimal glycemic control was not achieved, the other drug was added. If adverse effects occurred, the drug was replaced. If both failed, insulin was given. The primary outcomes were the rate of treatment failure and glycemic control after the first-line medication according to mean daily glucose charts. RESULTS Glyburide was started in 53 patients and metformin in 51. In the glyburide group, the drug failed in 18 (34%) patients due to adverse effects (hypoglycemia) in 6 (11%) and lack of glycemic control in 12 (23%). In the metformin group, the drug failed in 15 (29%) patients, due to adverse effects (gastrointestinal) in 1 (2%) and lack of glycemic control in 14 (28%). Treatment success after second-line therapy was higher in the metformin group than in the glyburide group (13 of 15 [87%] vs. 9 of 18 [50%], respectively; P = 0.03). In the glyburide group, nine (17%) patients were eventually treated with insulin compared with two (4%) in the metformin group (P = 0.03). The combination of the drugs reduced the need for insulin from 33 (32%) to 11 (11%) patients (P = 0.0002). Mean daily blood glucose and other obstetrical and neonatal outcomes were comparable between groups, including macrosomia, neonatal hypoglycemia, and electrolyte imbalance. CONCLUSIONS Glyburide and metformin are comparable oral treatments for GDM regarding glucose control and adverse effects. Their combination demonstrates a high efficacy rate with a significantly reduced need for insulin, with a possible advantage for metformin over glyburide as first-line therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin was associated with a lower risk of neonatal hypoglycemia and less maternal weight gain than insulin in systematic reviews and RCTs (78,(81)(82)(83).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [82]
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Criteria for screening tests for gestational diabetes
Carpenter, M. W., & Coustan, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90349-0 · Cited by 1,924 · cited 2×
“GDMdiagnosis was established by using Carpenter and Coustan (15) or”
MethodMetzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 8×
“Thus, glyburide might lead to fetal overgrowth and neonatal hypoglycemia through excessive fetal insulin secretion, whereas metformin increases insulin sensitivity in the target organswithout causing hyperinsulinism (2).”
BackgroundInfluentialA comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 3×
“We hypothesized that because the two medications act with different mechanisms (1,2), one would succeed where the other failed to achieve glycemic control and particularly if the medication was discontinued because of adverse effects.”
Background(2000) · doi:10.1016/s0261-3794(99)00028-1 · Cited by 620
Practice Bulletin No. 137: Gestational Diabetes Mellitus
(2013) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000433006.09219.f1 · Cited by 581
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
Hebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252
Metformin Compared With Glyburide in Gestational Diabetes: A Randomized Controlled Trial
Moore, L. E., Clokey, D., Rappaport, V. J., & Curet, L. B. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181c52132 · Cited by 177
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.74 · Cited by 177
Dhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145 · cited 3×
“Oral hypoglycemic drugs to treat GDM were suggested previously by studies that compared either glyburide or metformin to insulin, demonstrating comparable results (4).”
BackgroundResultGlyburide for the treatment of gestational diabetes
Kremer, C. J., & Duff, P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.02.032 · Cited by 126
Jiang, Y.-F., Chen, X.-Y., Ding, T., Wang, X.-F., Zhu, Z.-N., & Su, S.-W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4403 · Cited by 124
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000285 · Cited by 118
Metformin compared with glyburide for the management of gestational diabetes
Silva, J. C., Pacheco, C., Bizato, J., de Souza, B. V., Ribeiro, T. E., & Bertini, A. M. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.04.028 · Cited by 115 · cited 2×
“However, treatment failure leading to insulin use was ;25% and comparable in one study (10) but higher for metformin than for glyburide (35% vs.”
BackgroundPoolsup, N., Suksomboon, N., & Amin, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109985 · Cited by 107 · cited 2×
“distress, neonatal hypoglycemia, birth injury, increased birth weight, large-forgestational-age neonate, and macrosomia (3,13,14,19).”
BackgroundThe postprandial glucose profile in the diabetic pregnancy
Ben‐Haroush, A., Yogev, Y., Chen, R., Rosenn, B., Hod, M., & Langer, O. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.01.055 · Cited by 102
Glyburide transport across the human placenta
Schwartz, R. A., Rosenn, B., Aleksa, K., & Koren, G. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000672 · Cited by 83 · cited 1×
“that glyburide does not cross the placenta considerably (1,20), more-recent studies that used more sensitive methods to detect plasma concentrations of glyburide found that glyburide readily crosses the placenta, reaching 50–70% of total maternal plasma concentration with similar average concentrations of maternal and…”
BackgroundGeorge, A., Mathews, J. E., Sam, D., Beck, M., Benjamin, S. J., Abraham, A., Antonisamy, B., Jana, A. K., & Thomas, N. (2015) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12276 · Cited by 68
Glyburide for the treatment of gestational diabetes mellitus.
Kimber-Trojnar, Ż., Marciniak, B., Leszczyńska‐Gorzelak, B., Trojnar, M. P., & Oleszczuk, J. (2008) · PubMed · Cited by 21
Cited by
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s013 · Cited by 332
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
Metadata
- Authors
- Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam Ze Letova, Y., Suleiman, A., & Yefet, E.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Emek Medical Center (IL)
- Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel
- Corresponding author
- Yefet, Enav
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-01-11
- Volume
- 40
- Issue
- 3
- Pages
- 332-337
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2575922435
- Cited by
- 118
- References
- 21
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 4 · 2023: 10 · 2022: 10 · 2021: 37 · 2020: 12 · 2019: 11 · 2018: 16 · 2017: 7
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- gestational diabetes mellitus, glibenclamide, metformin, combination therapy, glycemic control, hypoglycemia, gastrointestinal adverse effects, insulin requirement, first-line therapy, macrosomia, neonatal hypoglycemia, electrolyte imbalance
- MeSH terms
- Administration, Oral, Adolescent, Adult, Blood Glucose, Drug Therapy, Combination, Female, Glyburide, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Israel, Metformin, Middle Aged, Pregnancy, Prospective Studies, Diabetes, Gestational, Treatment Outcome, Treatment Failure, Sample Size, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.